Deerfield describes itself as an investment firm dedicated to advancing healthcare through investment, intelligence and philanthropy, and says it holds a portfolio of more than two hundred private and public investments spanning therapeutics, medical devices, healthcare services, diagnostics and digital health. It states that it invests across capital structures and across company stages, from early-stage startups to mature companies, and that it offers structured finance solutions and customised financing for entrepreneurs and corporate partners in both public and private markets. Alongside the funds it runs an in-house research and data organisation: Deerfield Intelligence is described as the firm's data, technology and AI arm, and Deerfield Discovery and Development (3DC) as its internal R&D engine, taking early-stage therapeutics from discovery through preclinical proof of concept into clinical development. Deerfield also builds companies with academic and health-system partners through named discovery alliances. It is an SEC-registered investment adviser (CRD 157876, SEC file 801-73284) and files quarterly 13F reports covering listed equities, ADSs and convertible notes, so its public-market activity sits alongside its private investing rather than replacing it.
Nuvalent, Inc. (acquired by GSK, completed 15 July 2026, approximately $10.6 billion aggregate equity value)
Partner and Chief Financial Officer
Partner, General Counsel & Chief Compliance Officer
Partner and Chief Financial Officer, Funds
Partner and Chief Partnerships Officer
Partner and Chief Executive Officer, 3DC
Mark Michalski, M.D.
Chief Information Officer
Jennifer Pearson
Chief Human Resources Officer and Employment Counsel
Angelo Stornello
Chief Technology Officer
Karen Arnone
Chief Property and Development Officer
Alexis Caze
President, The Deerfield Foundation
1994
Deerfield Management Company is launched, per the firm's own About page.
2000
Jim Flynn joins Deerfield; he is now Managing Partner and, per his firm profile, responsible for the management of the firm.
2005
The Deerfield Foundation, the firm's New York City-based not-for-profit, is founded.
2020
Deerfield announces the close of Deerfield Healthcare Innovations Fund II at $840 million on 6 April 2020.
2021
Deerfield announces Deerfield Private Design Fund V, a $1.4 billion private investment fund, on 4 August 2021.
2023
Deerfield announces a $25M grant from New York State and Empire State Development to build a lab at its healthcare innovation campus, Cure, on 29 March 2023.
2024
Frank Nestle, M.D., FMedSci, joins from Sanofi as Partner and Chief Executive Officer of Deerfield Discovery and Development (3DC), announced 5 June 2024.
2025
Deerfield announces a collaboration with the Qatar Investment Authority as part of its fund of funds VC programme and the opening of a regional office in Doha, on 23 February 2025.
2025
Deerfield announces the close of a healthcare venture fund of over $600 million, named on the release as Healthcare Innovations Fund III, on 5 May 2025.
2025
Deerfield announces the sale of Melinta Therapeutics on 5 September 2025.
2026
Deerfield Strategic Growth Fund, L.P., a Delaware limited partnership formed in 2026, reports $121,500,000 sold in a Form D filed 13 April 2026.
2026
GSK completes its acquisition of Deerfield portfolio company Nuvalent, Inc. on 15 July 2026 for approximately $10.6 billion in aggregate equity value.